JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • October 25th, 2024 • Boxer Capital Management, LLC • Biological products, (no disgnostic substances)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G in respect of the Common Stock of Instil Bio, Inc. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein or therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • November 18th, 2024 • Boxer Capital Management, LLC • Biological products, (no disgnostic substances) • Delaware
This STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of November 14, 2024 (the “Effective Date”), by and among entities associated with BVF Partners L.P. (the “Purchaser”), on the one hand, and Boxer Capital, LLC, a Delaware limited liability company (“Seller”), on the other hand.
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • October 25th, 2024 • Boxer Capital Management, LLC • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G in respect of the Ordinary Shares of uniQure, N.V. is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein or therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)Joint Filing Agreement • November 18th, 2024 • Boxer Capital Management, LLC • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D and any amendments to it with respect to Common Stock, $0.001 par value per share, of iTeos Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to those joint filings. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
